Donepezil provides greater benefits in mild compared to moderate Alzheimer's disease: Implications for early diagnosis and treatment

Archives of Gerontology and Geriatrics

Volumn 52, Issue 1, 2011, Pages 18-22

  Molinuevo, J L ^a   Berthier, M L ^b   Rami, L ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

Alzheimer's disease; Cognition disorders; Donepezil; Drug therapy; Memory loss; Neuropsychology

Indexed keywords

DONEPEZIL;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG EFFECT; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; LANGUAGE; MAJOR CLINICAL STUDY; MALE; MEMORY; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEMANTIC MEMORY; TIME PERCEPTION; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; AGED; ALZHEIMER DISEASE; COGNITION; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; HUMANS; INDANS; MALE; MEMORY; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PIPERIDINES; PROSPECTIVE STUDIES;

EID: 78649705389     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archger.2009.11.004     Document Type: Article

References (35)

1. APA (American Psychiatric Association) Diagnostic and Statistical Manual of Mental Disorders (DSM IV) 1994, APA Press, Washington, DC. fourth ed.
2. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst. Rev. 2006, Art. No.: CD005593. 10.1002/14651858.CD005593.
3. Blesa R., Pujol M., Aguilar M., Santacruz P., Bertran-Serra I., Hernandez G., Sol J.M., Pena-Casanova J. Clinical validity of the 'mini-mental state' for Spanish speaking communities. Neuropsychologia 2001, 39:1150-1157.
4. Burns A., Gauthier S., Perdomo C. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease. Int. J. Geriatr. Psychiatry 2007, 22:806-812.
5. Courtney C., Farrell D., Gray R., Hills R., Lynch L., Sellwood E., Edwards S., Hardyman W., Raftery J., Crome P., Lendon C., Shaw H., Bentham P. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004, 363:2105-2115.
6. Doody R.S., Geldmacher D.S., Gordon B., Perdomo C.A., Pratt R.D. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch. Neurol. 2001, 58:427-433.
7. Drachman D.A., O'Donnell B.F., Lew R.A., Swearer J.M. The prognosis in Alzheimer's disease. 'How far' rather than 'how fast' best predicts the course. Arch. Neurol. 1990, 47:851-856.
8. Feldman H.H., Jacova C. Predicting response to acetylcholinesterase inhibitor treatment in Alzheimer disease: has the time come?. Nat. Clin. Pract. Neurol. 2009, 5:128-129. (Epub: 2009 February 3).
9. Feldman H., Gauthier S., Hecker J., Vellas B., Emir B., Mastey V., Subbiah P. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J. Am. Geriatr. Soc. 2003, 51:737-744. Donepezil MSAD Study Investigators Group.
10. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state" A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12:189-198.
11. Galasko D., Edland S.D., Morris J.C., Clark C., Mohs R., Koss E. The Consortium to establish a registry for Alzheimer's disease (CERAD). Part XI. Clinical milestones in patients with Alzheimer's disease followed over 3 years. Neurology 1995, 45:1451-1455.
12. Galasko D., Bennett D., Sano M., Ernesto C., Thomas R., Grundman M., Ferris S. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis. Assoc. Disord. 1997, 11(Suppl. 2):S33-S39.
13. Griffith P., Lichtenberg P., Goldman R., Payne-Parrish J. Safety and efficacy of donepezil in African Americans with mild-to-moderate Alzheimer's disease. J. Natl. Med. Assoc. 2006, 98:1590-1597.
14. Hansen R.A., Gartlehner G., Lohr K.N., Kaufer D.I. Functional outcomes of drug treatment in Alzheimer's disease: a systematic review and meta-analysis. Drugs Aging 2007, 24:155-167.
15. Holmes C., Wilkinson D., Dean C., Vethanayagam S., Olivieri S., Langley S., Pandita-Gunawardena N.D., Hogg F., Clare G., Damms J. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer's Disease. Neurology 2004, 63:214-219.
16. Kraemer H.C., Tinklenberg J., Yesavage J.A. 'How far' vs 'how fast' in Alzheimer's disease. The question revisited. Arch. Neurol. 1994, 51:275-279.
17. Kurz A., Farlow M., Quarg P., Spiegel R. Disease stage in Alzheimer disease and treatment effects of rivastigmine. Alzheimer Dis. Assoc. Disord. 2004, 18:123-128.
18. Lopez O.L., Mackell J.A., Sun Y., Kassalow L.M., Xu Y., McRae T., Li H. Effectiveness and safety of donepezil in Hispanic patients with Alzheimer's disease: a 12-week open-label study. J. Natl. Med. Assoc. 2008, 100:1350-1358.
19. Lopez-Pousa S., Robles A., Bermejo F., Masramon X., Rejas J., Leon T. Resultados del estudio Donald.es: cohorte de pacientes con EA leve a moderadamente grave tratados con donepezilo durante 2 años [abstract]. Neurologia 2006, 21:474-475. (in Spanish).
20. McCarten J.R., Rottunda S.J., Kuskowski M.A. Change in the mini-mental state exam in Alzheimer's disease over 2 years: the experience of a dementia clinic. J. Alzheimers Dis. 2004, 6:11-15.
21. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
22. Morris J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993, 43:2412-2414.
23. Morris J.C., Edland S., Clark C., Galasko D., Koss E., Mohs R., Van Belle G., Fillenbaum G., Heyman A. The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology 1993, 43:2457-2465.
24. NICE, 2009. Alzheimer's disease: donepezil, galantamine, rivastigmine (review) and memantine guidance (amended august 2009). http://www.nice.org.uk/TA111.
25. Rami L., Molinuevo J.L., Sanchez-Valle R., Bosch B., Villar A. Screening for amnestic mild cognitive impairment and early Alzheimer's disease with M@T (Memory Alteration Test) in the primary care population. Int. J. Geriatr. Psychiatry 2007, 22:294-304.
26. Rogers S.L., Doody R.S., Pratt R.D., Ieni J.R. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur. Neuropsychopharmacol. 2000, 10:195-203.
27. Saumier D., Murtha S., Bergman H., Phillips N., Whitehead V., Chertkow H. Cognitive predictors of donepezil therapy response in Alzheimer disease. Dement. Geriatr. Cogn. Disord. 2007, 24:28-35.
28. Seltzer B. Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment. J. Int. Med. Res. 2006, 34:339-347.
29. Seltzer B., Zolnouni P., Nunez M., Goldman R., Kumar D., Ieni J., Richardson S. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch. Neurol. 2004, 61:1852-1856.
30. Stern R.G., Mohs R.C., Davidson M., Schmeidler J., Silverman J., Kramer-Ginsberg E., Searcey T., Bierer L., Davis K.L. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am. J. Psychiatry 1994, 151:390-396.
31. Wallin A.K., Andreasen N., Eriksson S., Batsman S., Nasman B., Ekdahl A., Kilander L., Grut M., Ryden M., Wallin A., Jonsson M., Olofsson H., Londos E., Wattmo C., Eriksdotter Jonhagen M., Minthon L. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting. Dement. Geriatr. Cogn. Disord. 2007, 23:150-160.
32. Wattmo C., Hansson O., Wallin A.K., Londos E., Minthon L. Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting. Dement. Geriatr. Cogn. Disord. 2008, 26:203-211.
33. Winblad B., Engedal K., Soininen H., Verhey F., Waldemar G., Wimo A., Wetterholm A.L., Zhang R., Haglund A., Subbiah P. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001, 57:489-495.
34. Winblad B., Wimo A., Engedal K., Soininen H., Verhey F., Waldemar G., Wetterholm A.L., Haglund A., Zhang R., Schindler R. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement. Geriatr. Cogn. Disord. 2006, 21:353-363.
35. World Medical Association World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J. Postgrad. Med. 2002, 48:206-208.